TransMedics Group, Inc. $TMDX Shares Purchased by Taylor Frigon Capital Management LLC

Taylor Frigon Capital Management LLC boosted its stake in TransMedics Group, Inc. (NASDAQ:TMDX) by 30.0% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 34,986 shares of the company’s stock after acquiring an additional 8,078 shares during the period. TransMedics Group accounts for about 1.5% of Taylor Frigon Capital Management LLC’s holdings, making the stock its 20th biggest position. Taylor Frigon Capital Management LLC’s holdings in TransMedics Group were worth $2,920,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also recently added to or reduced their stakes in TMDX. Headlands Technologies LLC acquired a new stake in TransMedics Group during the 2nd quarter worth approximately $1,634,000. Candriam S.C.A. grew its stake in shares of TransMedics Group by 45.4% in the 1st quarter. Candriam S.C.A. now owns 158,766 shares of the company’s stock valued at $15,783,000 after purchasing an additional 49,580 shares during the last quarter. Emerald Investment Advisers LLC acquired a new position in shares of TransMedics Group in the second quarter valued at approximately $2,023,000. The Manufacturers Life Insurance Company acquired a new position in shares of TransMedics Group in the second quarter valued at approximately $1,140,000. Finally, Deutsche Bank AG acquired a new position in shares of TransMedics Group in the second quarter valued at approximately $14,415,000. Institutional investors and hedge funds own 99.67% of the company’s stock.

TransMedics Group Price Performance

Shares of TMDX opened at $70.74 on Friday. The company has a current ratio of 6.62, a quick ratio of 6.07 and a debt-to-equity ratio of 1.62. The stock’s 50 day moving average is $83.92 and its two-hundred day moving average is $81.96. TransMedics Group, Inc. has a twelve month low of $60.10 and a twelve month high of $156.00. The firm has a market capitalization of $2.44 billion, a PE ratio of 18.19, a P/E/G ratio of 0.97 and a beta of 1.94.

TransMedics Group (NASDAQ:TMDX) last released its quarterly earnings data on Tuesday, August 4th. The company reported $0.44 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.50 by ($0.06). The business had revenue of $189.95 million during the quarter, compared to analysts’ expectations of $184.00 million. TransMedics Group had a return on equity of 15.88% and a net margin of 22.69%. The company’s revenue was up 20.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.92 EPS. Research analysts anticipate that TransMedics Group, Inc. will post 1.46 earnings per share for the current year.

Analyst Ratings Changes

Several equities research analysts have recently commented on the company. Piper Sandler restated an “overweight” rating and set a $100.00 price target (down from $120.00) on shares of TransMedics Group in a research note on Wednesday, August 5th. Barclays began coverage on shares of TransMedics Group in a research report on Wednesday, October 7th. They issued an “overweight” rating and a $120.00 price objective on the stock. UBS Group dropped their price objective on shares of TransMedics Group from $80.00 to $77.00 and set a “neutral” rating on the stock in a research note on Wednesday, August 5th. Weiss Ratings upgraded shares of TransMedics Group from a “hold (c-)” rating to a “hold (c)” rating in a research report on Monday, August 31st. Finally, TD Cowen restated a “buy” rating and set a $120.00 price objective on shares of TransMedics Group in a research report on Tuesday, September 8th. Five investment analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, TransMedics Group has an average rating of “Hold” and a consensus price target of $115.60.

Insider Activity

In other TransMedics Group news, Director David Weill bought 1,336 shares of the business’s stock in a transaction on Friday, September 11th. The stock was bought at an average price of $81.63 per share, for a total transaction of $109,057.68. Following the completion of the transaction, the director owned 16,392 shares in the company, valued at approximately $1,338,078.96. The trade was a 8.87% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 6.90% of the stock is owned by company insiders.

About TransMedics Group

TransMedics Group, Inc is a medical technology company focused on improving organ transplantation through systems that preserve and assess donor organs outside the body. The company’s primary platform is the Organ Care System (OCS), a portable, technology-enabled perfusion system designed to maintain organs in a functioning, near-physiologic state during transport and evaluation.

TransMedics offers OCS products for heart, lung and liver transplantation. Its systems are intended to support the use of organs that may not otherwise be suitable for conventional cold-storage methods, potentially expanding the donor pool and providing transplant teams with additional information when evaluating organs for transplantation.

Founded in 1998 and headquartered in Andover, Massachusetts, TransMedics serves transplant centers in the United States and select international markets.